Atossa Therapeutics (ATOS) Competitors

Olema Pharmaceuticals (NASDAQ:OLMA) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Which has preferable valuation & earnings, OLMA or ATOS?

Atossa Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$96.65M	-$2.21	-2.33
Atossa Therapeutics	N/A	N/A	-$30.09M	-$0.21	-4.28

Which has more volatility and risk, OLMA or ATOS?

Olema Pharmaceuticals has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Do insiders & institutionals believe in OLMA or ATOS?

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are held by institutional investors. 19.4% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Atossa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Do analysts rate OLMA or ATOS?

Olema Pharmaceuticals presently has a consensus target price of $27.67, indicating a potential upside of 436.18%. Atossa Therapeutics has a consensus target price of $7.13, indicating a potential upside of 693.52%. Given Atossa Therapeutics' higher probable upside, analysts clearly believe Atossa Therapeutics is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Atossa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to OLMA or ATOS?

In the previous week, Atossa Therapeutics had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 8 mentions for Atossa Therapeutics and 7 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.94 beat Atossa Therapeutics' score of 0.55 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atossa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Is OLMA or ATOS more profitable?

Atossa Therapeutics' return on equity of -35.74% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-53.56%	-47.86%
Atossa Therapeutics	N/A	-35.74%	-33.51%

Does the MarketBeat Community prefer OLMA or ATOS?

Atossa Therapeutics received 206 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 71.15% of users gave Olema Pharmaceuticals an outperform vote while only 65.50% of users gave Atossa Therapeutics an outperform vote.

Company	Underperform	Outperform
Olema Pharmaceuticals	Outperform Votes 37 71.15%	Underperform Votes 15 28.85%
Atossa Therapeutics	Outperform Votes 243 65.50%	Underperform Votes 128 34.50%

Summary

Atossa Therapeutics beats Olema Pharmaceuticals on 7 of the 13 factors compared between the two stocks.